A phase IV, open, non-randomised, low-intervention clinical trial to evaluate the subjective user experience of Zeqmelit™ 6 mg mouth dissolving film for treatment of acute allergic reaction

Status

Completed

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504975-25-00

Acronym

ZEQ-001

Enrollment

Registered

2023-06-14

Start date

2024-01-26

Completion date

2024-10-24

Last updated

2023-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute allergic reaction

Brief summary

Overall satisfaction in terms of general satisfaction and feeling safe. (Questions: 1f/4h, 2i, 3a-d, 4a-g).

Detailed description

User experience in terms of choice of treatment, having access to treatment and other medication. (Questions: 2a-g, 2j-n, 3e-g)., Perceived effectiveness of Zeqmelit™ 6 mg mouth film. (Question: 2h).

Interventions

DRUGIsicort 6 mg munsönderfallande film

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall satisfaction in terms of general satisfaction and feeling safe. (Questions: 1f/4h, 2i, 3a-d, 4a-g).	—

Secondary

Measure	Time frame
User experience in terms of choice of treatment, having access to treatment and other medication. (Questions: 2a-g, 2j-n, 3e-g)., Perceived effectiveness of Zeqmelit™ 6 mg mouth film. (Question: 2h).	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026